Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis.

Abstract

The purpose of this analysis was to investigate whether the recommended daily dosage of 1-2mg/kg robenacoxib provides consistent exposure when administered to dogs with chronic osteoarthritis (OA), and the need for dose adjustment in special patient populations. Data from three prospective, multi-center field studies in 208 OA dogs were analyzed using non-linear mixed effects modeling. A model based assessment was performed with stepwise inclusion and exclusion of population characteristics to explain between-subject variability, and assess the according necessity for dose adjustment. Only the influence of bodyweight on both apparent clearance and volume were found to be significant (p<0.01). No significant influence of sex, age and breed, or kidney and liver variables was identified in this representative sample of OA dogs. The population pharmacokinetic analysis performed showed that the 1-2mg/kg dosage chosen provided consistent robenacoxib exposure in a wide range of canine patients. No other dose adjustment seems necessary.

• Authors: M Fink, I Letellier, M Peyrou, J P Mochel, M Jung, J N King, P Gruet, J M Giraudel
• Journal: Research in veterinary science (Res Vet Sci) Vol. 95 Issue 2 Pg. 580-7 (Oct 2013) ISSN: 1532-2661 [Electronic] England
• PMID: 23726662 (Publication Type: Journal Article)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Phenylacetates
• Diphenylamine
• robenacoxib

Topics

• Animals
• Anti-Inflammatory Agents, Non-Steroidal (blood, pharmacokinetics)
• Body Weight
• Chronic Disease
• Diphenylamine (analogs & derivatives, blood, pharmacokinetics)
• Dog Diseases (blood, drug therapy)
• Dogs
• Female
• Male
• Osteoarthritis (blood, drug therapy, veterinary)
• Phenylacetates (blood, pharmacokinetics)
• Sex Factors